BRCA2 and myelodysplastic syndrome: Interestingly, in the single patient with a detectable 40–60% VAF cfDNA BRCA2 mutation who did not undergo germline genetic testing, we also found co-existing 40–60% VAF cfDNA mutations in SRSF2 and STAG2. Both mutations are seen commonly in patients with myelodysplastic syndrome (MDS)15,16, and this patient did receive a subsequent diagnosis of MDS.